PCSK-9 inhibition in patients with recalcitrant hypercholesterolemia has reaped reductions in LDL-C of up to 85% after the first week of therapy.
Robert Giugliano, MD
Advertisement
Articles by Robert Giugliano, MD
Advertisement
Latest Updated Articles
- Lipid-lowering Injectable Antibodies: The Next Big Thing?
November 28th 2012
Advertisement
Advertisement
Trending on Patient Care Online
1
Reishi Mushroom Extract Outperformed Melatonin for Chronic Insomnia in New Study
2
GLP-1 Insurance Barriers Are Reshaping OSA Diagnostic Referral Patterns
3
Interpreting Smartwatch Sleep Metrics in Menopausal Patients, With Fiona Baker, PhD
4
Rural Patients at High Risk for Sleep Apnea Less Likely to Be Referred for Evaluation: SLEEP 2026
5